When analyzing only breast cancer patients who received chemotherapy (drugs not specified), there was a significant OS benefit in patients with high SLFN11 expression (HR = 4.32, p = 0.017) (Fig 3D). This evidence concerns the gene SLFN11 and breast cancer.